Expert Solutions for Drug Discovery Problems

We Provide Targeted Strategies to Overcome Your Toughest R&D Challenges

Scientist interacting with futuristic digital interface.

Accelerating Drug Discovery, Delivering Breakthroughs

Who We Are

At ShankarV Rx LLC, we bring over 20 years of proven leadership in drug discovery. From 7 IND filings to an FDA-approved therapy (Revumenib), we’ve successfully advanced programs across oncology, neurology, immunology, and metabolic diseases. Our consulting services are designed to help you overcome bottlenecks, optimize strategies, and maximize R&D investments.

What We Do

Checklist icon with checkmarks and circle.

Target Selection & Validation

Confidently choose the right targets with in-depth scientific and clinical assessments.

Graph with upward trend and gear symbol.

Hit Identification & Optimization

Expertise in SBDD, FBDD, HTS, DEL, and cheminformatics to find high-quality leads quickly.

Blue molecular structure on a black background.

Lead Optimization

Driving molecules to candidates through SAR, potency, selectivity, and ADMET balance.

Blue graph and magnifying glass illustration.

Preclinical Strategy

Translational study design that bridges discovery with IND-enabling development.

Light bulb with gear icon inside.

Innovative Modalities

PROTACs, molecular glues, cyclic peptides, and covalent/allosteric modulators.

Magnifying glass analyzing bar graphs illustration.

Data & Portfolio Review

Integrating chemistry, biology, DMPK, and safety to prioritize next steps.

Hand holding gear with checkmark icon.

Supporting academia

Supporting academia, and non-profit organizations, to assist in the identification of high-quality development candidates to enable reliable testing of therapeutic hypotheses in the clinic

Hand holding money bag and gear icon.

Supporting Early Start Up

Supporting early start up companies with funding, research plans, sourcing of CROs for research etc.

Why Work With Us—Proven Impact

  • 7 INDs Filed
  • 1 FDA-Approved Drug
  • $700M+ in upfront deals
  • $2B+ in milestone potential
  • 20+ years of global pharma & biotech leadership
Pills assortment; scientists examining tablet.